NEW YORK, May 19, 2017 /PRNewswire/ --
On Thursday, May 18, 2017, the NASDAQ Composite,
MYOS RENS Technology
Cedar Knolls, New Jersey-based MYOS RENS Technology Inc.'s stock finished Thursday's session 2.62% lower at $2.23, with a total trading volume of 40,352 shares. Since the start of this year, the Company's shares have advanced 88.98%. The stock is trading above its 200-day moving average by 2.23%. Moreover, shares of MYOS RENS Technology, which focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue, have a Relative Strength Index (RSI) of 40.34. See our free and comprehensive research report on MYOS at:
Shares in New York-based Akari Therapeutics PLC declined 3.39%, ending yesterday's session at $7.42, with a total trading volume of 55,081 shares. The stock has gained 6.00% in the previous three months and 5.40% on an YTD basis. The Company's shares are trading 18.04% below their 200-day moving average. Moreover, shares of Akari Therapeutics, which focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases, have an RSI of 34.11. AKTX free research report PDF is just a click away at:
On Thursday, Burlington, Massachusetts headquartered Flexion Therapeutics Inc.'s stock rose 0.17%, to close the day at $17.44. A total volume of 763,542 shares was traded, which was above their three months average volume of 721,380 shares. The Company's shares are trading 11.80% below their 200-day moving average. Additionally, shares of Flexion Therapeutics, which focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, have an RSI of 32.70. Sign up for your complimentary report on FLXN at:
Shares in Devon, Pennsylvania headquartered Zynerba Pharmaceuticals Inc. ended the day 2.74% higher at $18.77. A total volume of 287,749 shares was traded. The stock has gained 20.40% since the start of this year. The Company's shares are trading above their 200-day moving average by 16.72%. Furthermore, shares of Zynerba Pharma, which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery, have an RSI of 40.61. Register for free on Stock-Callers.com and download the latest research report on ZYNE at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All